[{"from": "human", "value": "Describe this molecule. [C][N][Branch2][Ring2][=Branch2][C][=C][Branch2][Ring2][Ring1][N][=C][Branch1][=Branch1][N][=C][Ring1][=Branch1][N][C][=N][N][Branch1][O][C][=C][Ring1][Branch1][C][=C][C][=N][Ring1][=Branch1][C][C][=C][C][=C][C][=C][Ring1][=Branch1][F][N][C][=Branch1][C][=O][O][C]"}, {"from": "gpt", "value": "The molecule is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III. Riociguat is marketed under the brand Adempas\u00ae by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment."}]